N@N

Inhibitex Announces Data Presentation at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL)

_{//health-fitness.news-articles.net/content/2011/ .. association-for-the-study-of-the-liver-easl.html}
^{Published in Health and Fitness on Thursday, March 31st 2011 at 0:20 GMT by Market Wire}  

ATLANTA--([ BUSINESS WIRE ])--Inhibitex, Inc. (NASDAQ: INHX) announced today the presentation of data from its single ascending dose Phase 1a study of INX-189 in healthy volunteers. The poster presentation will be presented by various scientists from the Company at the 46^th European Association for the study of the Liver in Berlin, Germany. The abstract can be viewed at the EASL website at [ www.easl.eu ].

"A STUDY OF THE SAFETY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF INX-08189, A NUCLEOTIDE POLYMERASE INHIBITOR, IN HEALTHY SUBJECTS"

The following poster will be presented during the Viral Hepatitis C: Clinical (Therapy) Poster Session, today, March 31, 2011, from 9:00 am - 6:00 pm CEST.

• ID #460; Barry et al.,aA STUDY OF THE SAFETY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF INX-08189, A NUCLEOTIDE POLYMERASE INHIBITOR, IN HEALTHY SUBJECTS"

The poster will be available in the INX-189 section of the Inhibitex website.

About Inhibitex

Inhibitex, Inc., a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Companya™s pipeline includes FV-100, which is in Phase II clinical development for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM^® protein platform to Pfizer for the development of staphylococcal vaccines. For additional information about the Company, please visit [ www.inhibitex.com ].

Inhibitex^® and MSCRAMM^® are registered trademarks of Inhibitex, Inc.